Nanobiotix to Participate in Global Investment Conference
PARIS and CAMBRIDGE, Mass. – Nanobiotix (Euronext: NANO – NASDAQ: NBTX), a leading clinical-stage biotechnology company, is set to appear at the prestigious H.C. Wainwright 27th Annual Global Investment Conference. Known for its groundbreaking approaches in nanoparticle-based cancer therapies, Nanobiotix aims to expand treatment possibilities for patients.
Fireside Chat Details
This significant event is scheduled for Tuesday, September 9th, 2025, at 9:00 am EDT / 3:00 pm CEST. Key personnel from Nanobiotix, including Laurent Levy, the Chief Executive Officer, and Bart van Rhijn, the Chief Financial & Business Officer, will lead the discussion. Their insights are expected to provide a comprehensive overview of the company's innovative strategies and future directions.
Webcast Information
Those interested in watching the fireside chat can access it live on the Investors section of the Company’s website. A recorded version will also be available post-event, allowing attendees to revisit the discussion on their own schedule.
About Nanobiotix
Founded in 2003 and headquartered in Paris, France, Nanobiotix is committed to revolutionizing treatment options for patients suffering from various ailments, including cancer. Their innovative physics-based technologies aim to redefine therapeutic outcomes for millions. As an entity listed on Euronext Paris and NASDAQ, the company prides itself on a philosophy of challenging limits and enhancing human life.
Achievements and Innovations
Nanobiotix holds more than 25 patent families related to three core nanotechnology platforms targeting oncology, bioavailability, and disorders of the central nervous system. Their continued research and development efforts aim not only at advancing scientific knowledge but also at delivering tangible improvements in patient care.
Company Growth and Outreach
With additional subsidiaries located in the United States, Nanobiotix actively collaborates with global partners to enhance its research capabilities and expand its market reach. This corporate evolution reflects the company's dedication to pioneering new therapeutic approaches and ensuring that cutting-edge cancer treatments are accessible to those in need.
Contact Information for Inquiries
For more details regarding Nanobiotix, interested parties can reach out via their communications department. Brandon Owens, the VP of Communications, is available at +1 (617) 852-4835 or through email for inquiries.
For investment-related questions, Joanne Choi, VP of Investor Relations for the US, and Ricky Bhajun, Director of Investor Relations for the EU, can be reached for precise information.
Frequently Asked Questions
What is the main focus of Nanobiotix?
Nanobiotix focuses on pioneering nanoparticle-based approaches to enhance cancer treatment options.
When is Nanobiotix participating in the conference?
Nanobiotix will participate in the H.C. Wainwright conference on September 9th, 2025.
Who will represent Nanobiotix at the conference?
Laurent Levy and Bart van Rhijn will represent Nanobiotix at the conference.
Where can I watch the fireside chat?
The fireside chat will be available live on the Company's website as well as a replay afterward.
How can I contact Nanobiotix for more information?
You can contact the communications department or investor relations via phone or email for inquiries.
